| scholarly article | Q13442814 |
| P50 | author | Grant McArthur | Q45893828 |
| Karen E Sheppard | Q55999216 | ||
| P2860 | cites work | Mutations of the BRAF gene in human cancer | Q27860760 |
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5320-5328 | |
| P577 | publication date | 2013-10-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma | |
| P478 | volume | 19 |
| Q61807258 | A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma |
| Q37106464 | A novel method to limit breast cancer stem cells in states of quiescence, proliferation or differentiation: Use of gel stress in combination with stem cell growth factors |
| Q40061875 | A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors |
| Q38644529 | A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors. |
| Q37710163 | AKT/GSK3β Signaling in Glioblastoma. |
| Q47200013 | Ablation of epidermal RXRα in cooperation with activated CDK4 and oncogenic NRAS generates spontaneous and acute neonatal UVB induced malignant metastatic melanomas |
| Q39456434 | Adenine Nucleotides Control Proliferation In Vivo of Rat Retinal Progenitors by P2Y1 Receptor. |
| Q26822793 | Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy |
| Q37616724 | Altered expression of G1/S phase cell cycle regulators in placental mesenchymal stromal cells derived from preeclamptic pregnancies with fetal-placental compromise. |
| Q38834777 | An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma |
| Q41819724 | An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia |
| Q36347006 | Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization |
| Q53705974 | BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers. |
| Q47115188 | Baicalein inhibits progression of osteosarcoma cells through inactivation of the Wnt/β-catenin signaling pathway |
| Q64054793 | Bcl-x inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas |
| Q36093810 | CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma |
| Q57571832 | CDK4 inhibitors an emerging strategy for the treatment of melanoma |
| Q93090401 | CDK5 suppresses the metastasis of gastric cancer cells by interacting with and regulating PP2A |
| Q35740051 | Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. |
| Q38917853 | Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment? |
| Q38815527 | Cell Cycle Regulation and Melanoma |
| Q38197938 | Clinical applications of melanoma genetics. |
| Q58610296 | Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine |
| Q56896764 | Combination therapies in advanced melanoma |
| Q38463905 | Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation |
| Q47876664 | Curcumin: Synthesis optimization and in silico interaction with cyclin dependent kinase |
| Q38970431 | Cyclin D1, cancer progression, and opportunities in cancer treatment. |
| Q36188947 | Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics |
| Q34359695 | DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations |
| Q64274553 | Different genetic mechanisms mediate spontaneous versus UVR-induced malignant melanoma |
| Q38936878 | Effect of adipose-derived stem cell-conditioned medium on the proliferation and migration of B16 melanoma cells |
| Q38725224 | Effects of CDKN2A (p16INK4A/p14ARF) Over-Expression on Proliferation and Migration of Human Melanoma A375 Cells |
| Q38946796 | FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia |
| Q64983501 | Familial risk of melanoma and links with other cancers. |
| Q92260584 | Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy |
| Q90185351 | Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer |
| Q41546576 | Genomic landscape of salivary gland tumors |
| Q41133627 | Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics |
| Q34667738 | Genotyping of cutaneous melanoma |
| Q39906311 | Histological Classification and Immunohistochemical Evaluation of MDM2 and CDK4 Expression in Canine Liposarcoma. |
| Q38221107 | Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment. |
| Q52729471 | In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. |
| Q92618729 | Increased CDK4 protein expression predicts a poor prognosis in mucosal melanoma associated with the p16INK4a-CDK4-pRb pathway |
| Q52579552 | Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma. |
| Q64236643 | It Takes a Team: A Gain-of-function Story of p53-R249S |
| Q52643170 | Lanthanide-based peptide biosensor to monitor CDK4/cyclin D kinase activity. |
| Q27852814 | Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines |
| Q34980366 | Loss of keratinocytic RXRα combined with activated CDK4 or oncogenic NRAS generates UVB-induced melanomas via loss of p53 and PTEN in the tumor microenvironment. |
| Q57571848 | Melanoma |
| Q38689912 | Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma |
| Q33560698 | Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation |
| Q34052520 | Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia |
| Q53307711 | Murine melanomas accelerated by a single UVR exposure carry photoproduct footprints but lack UV signature C>T mutations in critical genes. |
| Q34431264 | Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies |
| Q98771864 | Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications |
| Q38646138 | Novel Treatments in Development for Melanoma. |
| Q37697460 | Novel pyrrolidine diketopiperazines selectively inhibit melanoma cells via induction of late-onset apoptosis |
| Q38786230 | Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours. |
| Q26775594 | Other targeted drugs in melanoma |
| Q52724417 | P2Y12 but not P2Y13 Purinergic Receptor Controls Postnatal Rat Retinogenesis In Vivo. |
| Q37709050 | PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors. |
| Q37687790 | PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma |
| Q48113083 | Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance |
| Q26766708 | Phytochemicals for the Management of Melanoma |
| Q92137764 | Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion |
| Q92796910 | Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma |
| Q47595971 | Resistance mechanisms to genetic suppression of mutant NRAS in melanoma |
| Q40501839 | Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma. |
| Q50078440 | Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma |
| Q64937213 | SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib. |
| Q36685694 | Stanniocalcin 2 enhances mesenchymal stem cell survival by suppressing oxidative stress |
| Q36280711 | Sunrise in melanoma management: Time to focus on melanoma burden in Asia |
| Q50250079 | TP-2Rho Is a Sensitive Solvatochromic Red-Shifted Probe for Monitoring the Interactions between CDK4 and Cyclin D. |
| Q47590783 | Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer |
| Q38365261 | Targeting breast cancer with CDK inhibitors |
| Q35334436 | Targeting cell cycle regulators in hematologic malignancies. |
| Q26827580 | Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors |
| Q34914286 | The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death |
| Q90611117 | The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas |
| Q38148745 | The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. |
| Q26865888 | The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis |
| Q89896995 | Tissue Profile of CDK4 and STAT3 as Possible Innovative Therapeutic Targets in Urinary Bladder Cancer |
| Q38386344 | Treatment of NRAS-mutant melanoma. |
| Q33978378 | Understanding the biology of melanoma and therapeutic implications |
| Q43207599 | Unexpected role of CDK4 in a G2/M checkpoint |
| Q36274556 | Upregulated CDK16 Expression in Serous Epithelial Ovarian Cancer Cells. |
| Q91142660 | Upregulated expression of HOXB7 in intrahepatic cholangiocarcinoma is associated with tumor cell metastasis and poor prognosis |
| Q37022382 | Validation of a preclinical model for assessment of drug efficacy in melanoma |
Search more.